Adjuvant Therapy for Renal Cell Carcinoma Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Daniel Shapiro, MD, FACS CME Available: https://cme.auanet.org/URL/RCCPOD261 ACKNOWLEDGEMENTS: Support provided by an independent educational grant from: Merck & Co., Inc. LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Define adjuvant therapy, review current clinical guidelines, and recognize the current landscape of treatment options for patients with RCC. 2. Compare and contrast different adjuvant therapies available for RCC, including targeted therapies and immunotherapies. 3. Identify common side effects associated with adjuvant therapies for RCC and provide strategies for managing and mitigating these adverse events in clinical practice. 4. Discuss ongoing clinical trials and new therapeutic targets under investigation for adjuvant treatment of RCC.

AUA Guidelines: Advanced Prostate Cancer
4 views

Capitol Stream: Advancing Men’s Health on Capitol Hill
7 views

AUA2026: Focus on: Metastatic Urothelial Carcinoma (mUC)
92 views

Use of Ambient Listening AI Scribes: Improved Wellness and Efficiency in the Outpatient Setting
48 views

Global Perspectives: Lessons in Innovation, Resourcefulness, and Collaboration from Brazil
29 views

AUA Guidelines: Clinically Localized Prostate Cancer
292 views